Tag
This pooled analysis from COG studies reveals that after accounting for tumor biology, age, tumor nephrectomy weight, and diameter are not independently predictive of outcomes in stage I/II favorable histology Wilms tumor, refining risk str
This study evaluates how the number and positivity of lymph nodes affect survival outcomes in over 2,000 patients with stage I–III favorable histology Wilms tumor, underscoring the need for standardized lymph node sampling in surgical stagi
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
This study analyzes EBV infection and PTLD incidence in pediatric haploidentical HSCT, identifying prior CAR-T therapy, CMV viremia, and TBI conditioning as significant risk factors, with implications for enhanced monitoring and preemptive
Pediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailore
Prophylactic thyroidectomy in children with MEN2 mutations shows excellent short-term cancer control but carries notable risk of permanent hypoparathyroidism, especially under age 5, highlighting the need for expert multidisciplinary surgic
A comprehensive multicenter study reveals that ovarian immature teratomas with microscopic yolk sac tumor foci in pediatric patients have favorable outcomes, showing no increased recurrence risk despite higher tumor grade and stage.
A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn’t impact overall survi
A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Pa
This review analyzes the significant long-term thyroid toxicity burden in high-risk neuroblastoma survivors, identifying key risk factors such as molecular radiotherapy, tandem myeloablative therapy, and immunotherapy.
The BENCHISTA study analyzes survival disparities in six childhood solid tumors across 27 countries, revealing that while stage at diagnosis influences outcomes, significant international survival variations persist for Ewing sarcoma and me
Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standa
A Phase 2 trial by the Children’s Oncology Group found that denosumab, despite its success in other bone-related conditions, failed to meet efficacy benchmarks for recurrent or refractory osteosarcoma, showing no objective responses i
In AREN0533, number and size of pulmonary metastases had limited prognostic value after standardized therapy; gain of chromosome 1q emerged as a stronger, independent predictor of event‑free and overall survival in children with favorable‑h
A large cohort study links radiation exposure from pediatric medical imaging to a modest but significant increase in hematologic cancer risk, underlining the need for judicious imaging use in children and adolescents.
Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.
